Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandeep Dutta

Showing results (81-90 of 114) with videos related to

Pageof 12
Sort By:
Therapeutic Drug Monitoring|June 17, 2016
Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C InfectionPrajakta S Badri, Apurvasena Parikh, Eoin P Coakley, et al.
Clinical Pharmacology and Therapeutics|May 8, 2023
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Properties of Rozibafusp Alfa, a Bispecific Inhibitor of BAFF and ICOSL: Analyses of Phase I Clinical TrialsLubna Abuqayyas, Po-Wei Chen, Marcia Teixeira Dos Santos, et al.
Clinical Pharmacokinetics|March 23, 2016
Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I StudiesAkshanth R Polepally, Sven Mensing, Amit Khatri, et al.
Journal of Clinical Pharmacology|May 7, 2016
Pharmacokinetics and Tolerability of a Dual Variable Domain Immunoglobulin ABT-981 Against IL-1α and IL-1β in Healthy Subjects and Patients With Osteoarthritis of the KneeMatthew P Kosloski, Sandra Goss, Susanne X Wang, et al.
Journal of Clinical Pharmacology|September 11, 2023
Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC)Di Zhou, Lauren A Byers, Beate Sable, et al.
Clinical Drug Investigation|June 7, 2021
Effect of Omecamtiv Mecarbil on the Pharmacokinetics of Metformin, a Probe Substrate for MATE1/MATE2-K, in Healthy SubjectsAshit Trivedi, Rajneet K Oberoi, Pegah Jafarinasabian, et al.
Clinical and Translational Science|June 9, 2022
Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T-cellular therapy developmentJohannes Kast, Saeideh Nozohouri, Di Zhou, et al.
Epilepsia|February 27, 2007
Safety of rapid intravenous loading of valproateNita A Limdi, Robert K Knowlton, Stacey S Cofield, et al.
Clinical Therapeutics|October 28, 2015
Drug Interactions Between Hepatoprotective Agents Ursodeoxycholic Acid or Glycyrrhizin and Ombitasvir/Paritaprevir/Ritonavir in Healthy Japanese SubjectsJiuhong Zha, Prajakta S Badri, Bifeng Ding, et al.
Clinical Pharmacokinetics|July 9, 2016
Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal ImpairmentAmit Khatri, Sandeep Dutta, Thomas C Marbury, et al.
Pageof 12

Showing results (81-90 of 114) with videos related to

Sort By:
Pageof 12
Therapeutic Drug Monitoring|June 17, 2016
Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C InfectionPrajakta S Badri, Apurvasena Parikh, Eoin P Coakley, et al.
Clinical Pharmacology and Therapeutics|May 8, 2023
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Properties of Rozibafusp Alfa, a Bispecific Inhibitor of BAFF and ICOSL: Analyses of Phase I Clinical TrialsLubna Abuqayyas, Po-Wei Chen, Marcia Teixeira Dos Santos, et al.
Clinical Pharmacokinetics|March 23, 2016
Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I StudiesAkshanth R Polepally, Sven Mensing, Amit Khatri, et al.
Journal of Clinical Pharmacology|May 7, 2016
Pharmacokinetics and Tolerability of a Dual Variable Domain Immunoglobulin ABT-981 Against IL-1α and IL-1β in Healthy Subjects and Patients With Osteoarthritis of the KneeMatthew P Kosloski, Sandra Goss, Susanne X Wang, et al.
Journal of Clinical Pharmacology|September 11, 2023
Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC)Di Zhou, Lauren A Byers, Beate Sable, et al.
Clinical Drug Investigation|June 7, 2021
Effect of Omecamtiv Mecarbil on the Pharmacokinetics of Metformin, a Probe Substrate for MATE1/MATE2-K, in Healthy SubjectsAshit Trivedi, Rajneet K Oberoi, Pegah Jafarinasabian, et al.
Clinical and Translational Science|June 9, 2022
Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T-cellular therapy developmentJohannes Kast, Saeideh Nozohouri, Di Zhou, et al.
Epilepsia|February 27, 2007
Safety of rapid intravenous loading of valproateNita A Limdi, Robert K Knowlton, Stacey S Cofield, et al.
Clinical Therapeutics|October 28, 2015
Drug Interactions Between Hepatoprotective Agents Ursodeoxycholic Acid or Glycyrrhizin and Ombitasvir/Paritaprevir/Ritonavir in Healthy Japanese SubjectsJiuhong Zha, Prajakta S Badri, Bifeng Ding, et al.
Clinical Pharmacokinetics|July 9, 2016
Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal ImpairmentAmit Khatri, Sandeep Dutta, Thomas C Marbury, et al.
Pageof 12